Sanofi-Aventis S.A. ADR (SNY)

$42.95 -0.13 (-0.30%)
Market Cap 104.44B
Revenue (ttm) 52.85B
Net Income (ttm) 8.84B
EPS (ttm) N/A
PE Ratio 8.75
Forward PE 8.65
Profit Margin 16.72%
Debt to Equity Ratio 0.25
Volume 2,602,800
Avg Vol 3,542,632
Day's Range N/A - N/A
Shares Out 2.42B
Stochastic %K 36%
Beta 0.34
Analysts Sell
Price Target $53.39

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande ArmEe, Paris, France
MQuick
MQuick Aug. 3 at 4:24 PM
$GANX where u at $SNY
0 · Reply
PaulHeller1013
PaulHeller1013 Aug. 3 at 2:39 PM
$BNY $GSK $GD $SNY $SPOT BNY Mellon benefits from asset servicing, GSK advances pharmaceutical innovation, General Dynamics leads defense, Sanofi maintains a diversified drug portfolio, and Spotify dominates music streaming.
0 · Reply
CrispDry
CrispDry Aug. 2 at 10:27 PM
$ABVX just give us that $PFE or $SNY bomba tonight. I need to clear the drama and suspense
0 · Reply
clan
clan Aug. 2 at 1:32 AM
$LLY 😲 $NVO 😲 $SNY Who here knew there now exists an INHALABLE mealtime insulin for diabetics ages 6 and up ! 😲 No needles! That's awesome! For the good of all Mannkind. Made in the U.S.A.! 🇺🇲
0 · Reply
7xbagger
7xbagger Aug. 2 at 12:54 AM
$VXRT (my buyout price) 1 Sanofi share $SNY + $6.66 per share for first 10%. .. higher if you don't act soon.. (the other 90% not for sale at this time)
2 · Reply
artiebet
artiebet Aug. 1 at 2:56 AM
You dont say $SNY .... Heard $ALT is all dressed up & ready for the ball? Don't make us whip out the breakthrough oral.
1 · Reply
AutoAZTrader
AutoAZTrader Jul. 31 at 2:32 PM
$SNY Hate these stocks that don't move with the market; not trading this again.
0 · Reply
Joker_Nicholson
Joker_Nicholson Jul. 31 at 11:43 AM
$NVO $LLY $SNY ➡️ $ALT 👀
1 · Reply
alexx013
alexx013 Jul. 30 at 4:39 PM
$SNY reentered @ 41.9
0 · Reply
clan
clan Jul. 30 at 3:24 PM
$LLY 😲 $NVO 👀 $SNY Who knew?!? Wow!
0 · Reply
Latest News on SNY
Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100

2026-07-30T22:32:05.000Z - 4 days ago

Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100

Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges

2026-07-30T16:32:28.000Z - 4 days ago

Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges

Sanofi: Sanofi's half-year financial report for 2026

2026-07-30T13:46:00.000Z - 4 days ago

Sanofi: Sanofi's half-year financial report for 2026

Sanofi Q2 Earnings Call Highlights

Thu, 30 Jul 2026 09:05:31 -0400 - 4 days ago

Sanofi Q2 Earnings Call Highlights

Sanofi Q2 Earnings Call Highlights

2026-07-30T13:04:10.000Z - 4 days ago

Sanofi Q2 Earnings Call Highlights

Sanofi Earnings Call Transcript: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 4 days ago

Sanofi Earnings Call Transcript: Q2 2026

Sanofi Earnings release: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 4 days ago

Sanofi Earnings release: Q2 2026

Sanofi Slides: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 4 days ago

Sanofi Slides: Q2 2026

Sanofi Earnings release: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 4 days ago

Sanofi Earnings release: Q2 2026

Sanofi Quarterly report: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 4 days ago

Sanofi Quarterly report: Q2 2026

Sanofi expects FY26 sales to grow by around 10% at CER

2026-07-30T10:26:32.000Z - 4 days ago

Sanofi expects FY26 sales to grow by around 10% at CER

SNY

Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported

2026-07-30T10:20:53.000Z - 4 days ago

Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported

SNY

Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook

2026-07-30T06:02:24.000Z - 4 days ago

Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook

Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline

Jul 30, 2026, 1:44 AM EDT - 4 days ago

Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline

SNY

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

Jul 30, 2026, 1:34 AM EDT - 4 days ago

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

SNY

Sanofi: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded

2026-07-30T05:34:00.000Z - 4 days ago

Sanofi: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded

Sanofi SA (SNY) Stock Up 3.5% and Still Undervalued -- GF Score: 72/100

2026-07-28T22:23:11.000Z - 6 days ago

Sanofi SA (SNY) Stock Up 3.5% and Still Undervalued -- GF Score: 72/100

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Jul 24, 2026, 2:32 AM EDT - 10 days ago

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

SNY

Sanofi Ends Clinical Development Of Amlitelimab For Atopic Dermatitis

2026-07-24T06:24:00.000Z - 10 days ago

Sanofi Ends Clinical Development Of Amlitelimab For Atopic Dermatitis

Sanofi: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

2026-07-24T05:34:00.000Z - 10 days ago

Sanofi: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Jul 24, 2026, 1:30 AM EDT - 10 days ago

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

SNY

Scribe Therapeutics Sets IPO Of 8.58 Mln Shares At $15/Shr; Enters Private Placement With Sanofi

2026-07-24T05:17:27.000Z - 10 days ago

Scribe Therapeutics Sets IPO Of 8.58 Mln Shares At $15/Shr; Enters Private Placement With Sanofi

Sanofi announces Executive Committee to support next strategic chapter

2026-07-21T16:10:19.000Z - 13 days ago

Sanofi announces Executive Committee to support next strategic chapter

SNY

Sanofi: Sanofi evolves its Executive Committee to support its next strategic chapter

2026-07-21T16:10:00.000Z - 13 days ago

Sanofi: Sanofi evolves its Executive Committee to support its next strategic chapter

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Jul 21, 2026, 12:00 PM EDT - 13 days ago

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

SNY

Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase

2026-07-20T17:37:37.000Z - 14 days ago

Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase

Aqemia and Sanofi Expand Their Research Collaboration

Jul 17, 2026, 6:30 AM EDT - 17 days ago

Aqemia and Sanofi Expand Their Research Collaboration

SNY

Sanofi sues Pfizer, Moderna over COVID shot technology

2026-07-15T16:01:55.389Z - 19 days ago

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma

2026-07-10T15:00:52.000Z - 24 days ago

Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma

Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena

2026-07-10T14:26:33.000Z - 24 days ago

Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena

Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector

2026-07-10T13:33:13.000Z - 24 days ago

Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector

Sanofi: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

2026-07-10T12:46:00.000Z - 24 days ago

Sanofi: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Sanofi announces subcutaneous Sarclisa Escena approved in U.S.

2026-07-10T12:45:28.000Z - 24 days ago

Sanofi announces subcutaneous Sarclisa Escena approved in U.S.

SNY

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Jul 10, 2026, 8:35 AM EDT - 24 days ago

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

SNY

US FDA approves Sanofi's wearable injector form of blood cancer drug

Jul 10, 2026, 8:22 AM EDT - 24 days ago

US FDA approves Sanofi's wearable injector form of blood cancer drug

SNY

Sanofi price target lowered to $49 from $52 at Morgan Stanley

2026-07-08T11:30:49.000Z - 26 days ago

Sanofi price target lowered to $49 from $52 at Morgan Stanley

SNY

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

Jul 8, 2026, 6:00 AM EDT - 26 days ago

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

SNY

Press Release: Availability of the aide-mémoire for Q2 2026 results

Jul 1, 2026, 1:30 AM EDT - 4 weeks ago

Press Release: Availability of the aide-mémoire for Q2 2026 results

SNY

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Tue, 30 Jun 2026 15:04:19 -0400 - 4 weeks ago

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 5 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE JNJ LLY MRNA SNY

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

Jun 26, 2026, 5:46 AM EDT - 5 weeks ago

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

SNY

Press Release: Sanofi Foundation opens new chapter centered on future generations

Jun 25, 2026, 2:00 AM EDT - 5 weeks ago

Press Release: Sanofi Foundation opens new chapter centered on future generations

SNY

Sanofi Multiple Sclerosis Drug Gets EU Approval

Jun 23, 2026, 1:37 AM EDT - 5 weeks ago

Sanofi Multiple Sclerosis Drug Gets EU Approval

SNY

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Jun 23, 2026, 1:15 AM EDT - 5 weeks ago

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

ITP SNY

MacroGenics to receive $24.5M milestone payment from Sanofi

2026-06-22T20:45:10.000Z - 6 weeks ago

MacroGenics to receive $24.5M milestone payment from Sanofi

MGNX SNY

Sanofi appoints Paulo Fontoura as Global Head of R&D

2026-06-22T13:30:14.000Z - 6 weeks ago

Sanofi appoints Paulo Fontoura as Global Head of R&D

SNY

Sanofi investors likely to view new R&D head as a positive, says BofA

2026-06-22T13:26:54.000Z - 6 weeks ago

Sanofi investors likely to view new R&D head as a positive, says BofA

SNY

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Jun 22, 2026, 2:00 AM EDT - 6 weeks ago

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

SNY

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Jun 19, 2026, 6:31 AM EDT - 6 weeks ago

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

SNY

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

2026-06-15T16:16:28.000Z - 7 weeks ago

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

SNY

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Jun 15, 2026, 12:05 PM EDT - 7 weeks ago

Sanofi: Information concerning the total number of voting rights and shares – May 2026

SNY

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Jun 12, 2026, 5:19 PM EDT - 7 weeks ago

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

SNY

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

Jun 12, 2026, 8:22 AM EDT - 7 weeks ago

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

SNY

Sanofi ends Phase 3 riliprubart trial after weak interim results

Jun 10, 2026, 2:38 AM EDT - 7 weeks ago

Sanofi ends Phase 3 riliprubart trial after weak interim results

SNY

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Jun 10, 2026, 2:28 AM EDT - 7 weeks ago

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

SNY

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Jun 10, 2026, 1:00 AM EDT - 7 weeks ago

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Jun 5, 2026, 7:00 AM EDT - 2 months ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Press Release: Sanofi launches 2026 global employee stock purchase plan

Jun 4, 2026, 4:07 AM EDT - 2 months ago

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 2 months ago

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026, 12:37 PM EDT - 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - April 2026

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026, 3:36 PM EDT - 2 months ago

Sanofi says rare lung disease drug outperforms standard care in trial

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026, 3:30 PM EDT - 2 months ago

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026, 2:38 PM EDT - 3 months ago

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026, 12:42 PM EDT - 3 months ago

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Apr 29, 2026, 12:00 PM EDT - 3 months ago

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Apr 24, 2026, 2:30 PM EDT - 3 months ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Apr 24, 2026, 6:09 AM EDT - 3 months ago

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Sanofi Earnings Call Transcript: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Sanofi Earnings Call Transcript: Q1 2026

Sanofi Slides: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Sanofi Slides: Q1 2026

Sanofi Earnings release: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Sanofi Earnings release: Q1 2026

Sanofi Posts Higher Sales Amid Leadership Transition

Apr 23, 2026, 2:08 AM EDT - 3 months ago

Sanofi Posts Higher Sales Amid Leadership Transition

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Apr 23, 2026, 1:35 AM EDT - 3 months ago

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Apr 22, 2026, 5:30 PM EDT - 3 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

REGN

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Apr 22, 2026, 1:05 AM EDT - 3 months ago

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Apr 22, 2026, 1:00 AM EDT - 3 months ago

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Apr 13, 2026, 1:00 AM EDT - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

REGN

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Apr 7, 2026, 1:00 AM EDT - 4 months ago

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Mar 31, 2026, 1:00 AM EDT - 4 months ago

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Mar 28, 2026, 11:00 AM EDT - 4 months ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

EU regulator backs Sanofi's injectable version of blood cancer drug

Mar 27, 2026, 9:36 AM EDT - 4 months ago

EU regulator backs Sanofi's injectable version of blood cancer drug

Press release: Availability of the Q1 2026 aide-mémoire

Mar 24, 2026, 2:30 AM EDT - 4 months ago

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Mar 24, 2026, 2:00 AM EDT - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

REGN

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Mar 23, 2026, 7:57 AM EDT - 4 months ago

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Sanofi launches innovation and operation centre in China

Mar 20, 2026, 10:58 AM EDT - 4 months ago

Sanofi launches innovation and operation centre in China

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 4 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

MQuick
MQuick Aug. 3 at 4:24 PM
$GANX where u at $SNY
0 · Reply
PaulHeller1013
PaulHeller1013 Aug. 3 at 2:39 PM
$BNY $GSK $GD $SNY $SPOT BNY Mellon benefits from asset servicing, GSK advances pharmaceutical innovation, General Dynamics leads defense, Sanofi maintains a diversified drug portfolio, and Spotify dominates music streaming.
0 · Reply
CrispDry
CrispDry Aug. 2 at 10:27 PM
$ABVX just give us that $PFE or $SNY bomba tonight. I need to clear the drama and suspense
0 · Reply
clan
clan Aug. 2 at 1:32 AM
$LLY 😲 $NVO 😲 $SNY Who here knew there now exists an INHALABLE mealtime insulin for diabetics ages 6 and up ! 😲 No needles! That's awesome! For the good of all Mannkind. Made in the U.S.A.! 🇺🇲
0 · Reply
7xbagger
7xbagger Aug. 2 at 12:54 AM
$VXRT (my buyout price) 1 Sanofi share $SNY + $6.66 per share for first 10%. .. higher if you don't act soon.. (the other 90% not for sale at this time)
2 · Reply
artiebet
artiebet Aug. 1 at 2:56 AM
You dont say $SNY .... Heard $ALT is all dressed up & ready for the ball? Don't make us whip out the breakthrough oral.
1 · Reply
AutoAZTrader
AutoAZTrader Jul. 31 at 2:32 PM
$SNY Hate these stocks that don't move with the market; not trading this again.
0 · Reply
Joker_Nicholson
Joker_Nicholson Jul. 31 at 11:43 AM
$NVO $LLY $SNY ➡️ $ALT 👀
1 · Reply
alexx013
alexx013 Jul. 30 at 4:39 PM
$SNY reentered @ 41.9
0 · Reply
clan
clan Jul. 30 at 3:24 PM
$LLY 😲 $NVO 👀 $SNY Who knew?!? Wow!
0 · Reply
hgarrett
hgarrett Jul. 30 at 2:59 PM
$SNY added
0 · Reply
DonCorleone77
DonCorleone77 Jul. 30 at 1:15 PM
$AMCX $NCLH $SNY $MO $QCOM PRE-MARKET MOVERS: Currently Higher After Earnings: - Baxter (BAX) up 14.9% - Quanta Services (PWR) up 13.2% - Lam Research (LRCX) up 14.1% - Form Factor (FORM) up 21.1% - Fortinet (FTNT) up 12.3% - Microsoft (MSFT) up 9.8% - Chipotle (CMG) up 8.3% - ING Groep (ING) up 5.6% - Lloyds Banking (LYG) up 4.6% - Starbucks (SBUX) up 4.6% - Oil States (OIS) up 4.4% - Shell (SHEL) up 1.9% - Wesco (WCC) up 8.2% Currently Also Higher: - MarketAxess (MKTX) up 29.7% after Intercontinental Exchange (ICE) announced a definitive agreement to acquire the company for $167 per share in cash Currently Lower After Earnings: - Teladoc (TDOC) down 18.1% - Meta Platforms (META) down 9.0% - Sirius XM (SIRI) down 7.7% - Check Point (CHKP) down 10.4% - Carvana (CVNA) down 9.2% - AMC Networks (AMCX) down 0.9% - Norwegian Cruise Line (NCLH) down 7.0% - Sanofi (SNY) down 5.6%. - Altria Group (MO) down 5.3% - Qualcomm (QCOM) down 4.1% - AB InBev (BUD) down 2.2% - Bristol Myers (BMY) down 1.4%
0 · Reply
GoforProMIS
GoforProMIS Jul. 30 at 11:43 AM
$PMN and for ALS with FTD&MSA the takeover pharmaceutical companies are $SNY ,$SDZXF if not new player joins in like$PFE or any other big Pharma player!
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 30 at 10:36 AM
$SNY Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.14 down -91.36% YoY • Reported revenue of $12.3B up 14.58% YoY • In 2026, Sanofi expects sales to grow by around 10% at constant exchange rates, with Sanofi business earnings per share at constant exchange rates expected to grow slightly faster than sales.
0 · Reply
Estimize
Estimize Jul. 30 at 10:01 AM
$SNY reported - EPS and - revenue for Q2. http://www.estimize.com/intro/sny?chart=historical&metric_name=eps&utm_content=SNY&utm_medium=act
0 · Reply
27R
27R Jul. 29 at 6:26 PM
$SNY Buckle up — earnings before the open tomorrow.
0 · Reply
MQuick
MQuick Jul. 29 at 1:34 PM
$GANX its time $SNY or $ABBV
0 · Reply
Estimize
Estimize Jul. 28 at 10:06 PM
Wall St is expecting 1.09 EPS for $SNY Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/sny?chart=historical&metric_name=eps&utm_cont
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 28 at 5:45 PM
$SNY Does anyone here believe it would be beneficial for Sanofi to acquire TGTX (TG Therapeutics)? TGTX would immediately begin to contribute to SNY’s cash flow, etc. For funding, SNY has vast cash flow to secure a multi-billion-dollar revenue stream w/o destabilizing its debt profile.
1 · Reply
CrispDry
CrispDry Jul. 27 at 11:49 PM
$ABVX let’s gooo $AZN $SNY
1 · Reply
MQuick
MQuick Jul. 27 at 7:48 PM
$GANX its time $SNY
0 · Reply
clan
clan Jul. 26 at 1:03 AM
$NVO $SNY Diabetics, NO MORE NEEDLES! Just INHALE!
1 · Reply